uyen Ngo Quang, Deputy Director of the Department of Science, Technology and Training (Ministry of Health),appreciated the cooperation between Takeda and VNVC,under which Vietnamese people are expected to soon have access to a dengue vaccine.
At the signing ceremony, the two sides agreed to implement important activities to promote awareness and improve the professional knowledge of medical workers on dengue prevention measures, including the dengue vaccine.
Takeda’s dengue vaccine, TAK-003 (registered tradename QDENGA), has been licensed in more than 30 countries, including the European Union (EU), the UK, Argentina, and countries with dengue epidemiological patterns similar to that of Vietnam such as Indonesia, Brazil, and Thailand.
TAK-003 has yet to be licensed in Vietnam. Test results showed that the vaccine can create immune responses at different levels to all four serotypes of dengue virus in the world, helping to prevent disease and reduce the possibility of hospitalisation among people with dengue.
According to the European Medicines Agency (EMA), the unit that licensed the use of the vaccine in the EU,QDENGA vaccine was approved for children from 4 years old, regardless of whether they have ever been infected or not.
